Phexin
Phexin Price range: $ 70,00 through $ 374,00
Back to products
Pilex
Pilex Price range: $ 49,00 through $ 295,00

PhosLo

Price range: $ 48,00 through $ 217,00

PhosLo is a highly effective phosphate binder formulated with calcium acetate to help manage mineral levels in patients with end-stage renal disease. This medication works by binding to dietary phosphorus in the digestive tract, effectively preventing its absorption into the bloodstream. By controlling phosphorus levels, PhosLo plays a vital role in maintaining bone health and preventing the complications associated with hyperphosphatemia. For optimal results, these capsules are taken with every meal to capture phosphorus from food before it can affect the body. Incorporating PhosLo into a daily routine provides essential support for individuals on dialysis who need to regulate their mineral balance.

Active substance: Calcium Acetate
SKU: PhosLo Categories: , ,
Delivery: 5–21 days (depending on the shipping method)
Extra 10% discount with coupon: IT4K6SVM

Each dosage option has its own packaging choices.

Description

PhosLo belongs to a class of medications known as phosphate binders, specifically containing calcium acetate as its active pharmaceutical ingredient. It is approved by the U.S. Food and Drug Administration (FDA) for reducing serum phosphorus levels in adult patients suffering from end-stage renal disease (ESRD) who are undergoing hemodialysis or peritoneal dialysis.

When administered orally with meals, calcium acetate binds to dietary phosphate in the gastrointestinal tract, forming an insoluble calcium phosphate precipitate that is subsequently excreted in the feces. Management of hyperphosphatemia with this prescription medication requires regular clinical monitoring of serum calcium and phosphorus concentrations to prevent severe metabolic complications.

Basic Information

Drug Name PhosLo
Active Ingredient Calcium acetate
Primary Purpose Reduction of serum phosphorus in end-stage renal disease (ESRD)
Prescription Status Prescription drug (Rx only)
Dosage Form Oral gelcaps (667 mg calcium acetate)
Route of Administration Oral
Storage 20°C to 25°C (68°F to 77°F); controlled room temperature

Prescribing Information and Clinical Profile

Main Uses and Mechanism of Action

Main Uses

PhosLo is indicated for the control of hyperphosphatemia in patients with end-stage renal disease (ESRD) maintained on chronic dialysis, including both hemodialysis and peritoneal dialysis. Hyperphosphatemia is a frequent complication in patients with severe renal impairment, resulting from the kidney’s impaired capacity to filter and excrete inorganic phosphate. Excess serum phosphorus contributes to renal osteodystrophy, secondary hyperparathyroidism, and progressive calcification of vascular and soft tissues. By binding phosphate directly in the digestive lumen during meals, PhosLo prevents systemic absorption of dietary phosphorus. Off-label use of PhosLo in patients with moderate chronic kidney disease (CKD stages 3 or 4) who are not on dialysis is not established as safe or effective under the primary FDA label and must be evaluated by a nephrologist.

How the Drug Works

The therapeutic mechanism of PhosLo relies on a chemical precipitation process within the gastrointestinal tract. When taken orally alongside meals, calcium acetate dissociates in the stomach and small intestine into calcium ions and acetate ions. The ionized calcium selectively reacts with inorganic phosphate ions provided by dietary proteins and food additives. This chemical reaction yields insoluble calcium phosphate salts, such as hydroxylapatite or amorphous calcium phosphate, which cannot pass through the intestinal mucosa into systemic circulation. Instead, the bound phosphate complexes remain within the digestive lumen and are eliminated through fecal excretion. Consequently, systemic absorption of dietary phosphorus is substantially diminished, helping maintain serum phosphorus levels within acceptable clinical ranges (typically below 5.5 mg/dL).

Dosing Schedule and Pharmacokinetics

Dosing Schedule

The dosage of PhosLo must be individualized based on serum phosphorus measurements and ongoing clinical response. The standard initial dosage for adult ESRD patients on dialysis is 2 gelcaps (667 mg calcium acetate per gelcap, equivalent to 169 mg elemental calcium per unit) taken orally with each meal. A typical starting regimen consists of 2 gelcaps three times daily during breakfast, lunch, and dinner. The dosage is gradually titrated upward by 1 or 2 gelcaps per meal at intervals of two to three weeks until the target serum phosphorus level is achieved, provided hypercalcemia does not develop. Most patients require 3 to 4 gelcaps per meal to maintain target phosphate control. PhosLo must always be ingested during or immediately preceding meals to maximize direct contact with ingested food.

What Happens in the Body

From a pharmacokinetic perspective, PhosLo exerts its primary pharmacodynamic effect locally within the gastrointestinal tract rather than through systemic bioavailability. Calcium acetate dissolves rapidly in gastric secretions, allowing immediate reaction with available dietary phosphate. However, a portion of the solubilized calcium ions is systemically absorbed across the intestinal epithelium into the bloodstream. The extent of calcium absorption varies depending on gastrointestinal pH, baseline vitamin D status, and concurrent systemic calcium balance. Absorbed calcium is subject to renal handling or incorporation into bone matrix, but in ESRD patients with minimal residual kidney function, renal clearance of excess systemic calcium is severely impaired. Unbound acetate ions undergo normal hepatic metabolism into bicarbonate and carbon dioxide. The unabsorbed calcium phosphate complex passes intact through the colon for fecal elimination.

Missed Dose

If a dose of PhosLo is missed at the time of a meal, the patient should skip the missed dose entirely if the meal has already passed. Because calcium acetate works specifically by binding phosphate present in food, administering the dose on an empty stomach between meals offers minimal benefit for phosphate binder activity and increases the risk of systemic calcium absorption and hypercalcemia. Patients should not double up doses at the next meal to compensate for a skipped dose. Resume the prescribed regimen with the next scheduled meal.

What Not to Combine and What to Avoid

What Not to Combine

PhosLo can alter the absorption kinetics of several co-administered oral medications by forming non-absorbable chelates or altering gastrointestinal pH. Fluoroquinolone antibiotics (such as ciprofloxacin and levofloxacin) and tetracyclines (such as doxycycline) experience significant reduction in bioavailability when taken concurrently; these antibiotics should be administered at least 1 to 2 hours before or 3 to 4 hours after PhosLo. Levothyroxine and oral iron supplements should also be separated from PhosLo by at least 2 to 4 hours to prevent impaired systemic absorption. Concomitant administration of cardiac glycosides like digoxin requires extreme caution, as any resulting hypercalcemia can precipitate fatal cardiac arrhythmias. Furthermore, combined use with thiazide diuretics or high-dose vitamin D analogs increases the likelihood of developing systemic hypercalcemia.

What to Avoid While Taking It

Patients taking PhosLo should adhere to dietary restrictions established by their nephrologist or renal dietitian. High-phosphate foods (such as dairy products, nuts, processed meats, and dark sodas) should still be restricted, as phosphate binders supplement rather than replace dietary management. Excessive intake of calcium-fortified foods or over-the-counter calcium supplements should be avoided to reduce the risk of hypercalcemia. Alcohol does not directly interfere with the chemical binding of calcium acetate; however, heavy alcohol consumption can alter fluid management and dietary compliance, potentially complicating ESRD management in clinical settings such as dialysis centers in Texas or New York.

Important Precautions and Adverse Reactions

Important Precautions

PhosLo is contraindicated in patients with pre-existing hypercalcemia. Regular laboratory evaluation of serum calcium and serum phosphorus is mandatory, ideally twice weekly during initial dose titration. Chronic hypercalcemia in ESRD patients can lead to vascular calcification, soft tissue calcification, and severe cardiovascular pathology. If mild hypercalcemia occurs (serum calcium 10.5 mg/dL to 12.0 mg/dL), the dosage of PhosLo should be reduced, or concurrent vitamin D therapy adjusted. If serum calcium exceeds 12.0 mg/dL, PhosLo therapy must be temporarily discontinued until normal calcium balance is restored. In geriatric patients, careful monitoring is advised due to higher rates of concurrent cardiac medications. Safety and effectiveness in pediatric patients have not been established in clinical trials.

Adverse Reactions

The most significant clinical side effect associated with PhosLo is hypercalcemia, which can range from asymptomatic mild elevations to severe hypercalcemia. Symptoms of hypercalcemia include confusion, lethargy, muscle weakness, nausea, vomiting, constipation, anorexia, and cardiac dysrhythmias. Gastrointestinal adverse effects are relatively common and include mild nausea, constipation, diarrhea, flatulence, abdominal pain, and abdominal distension. Patients experiencing severe abdominal pain, persistent vomiting, or signs of systemic calcification (such as painful skin lesions) must contact their healthcare provider immediately. Adjusting the dosage or changing to non-calcium-based phosphate binders may be required if intolerable gastrointestinal symptoms or recalcitrant hypercalcemia persist.

What to Ask Your Provider

Patients prescribed PhosLo should maintain open communication with their renal care team. Recommended topics of discussion include clarifying the exact timing of doses relative to meals, reviewing all concurrent prescription and over-the-counter medications to prevent drug-drug interactions, and understanding target serum phosphorus levels. Patients should also inquire about how to recognize early signs of elevated blood calcium levels and whether dietary calcium restriction is required based on ongoing laboratory blood work.

Storage and Expiration

PhosLo gelcaps should be stored at controlled room temperature between 20°C and 25°C (68°F to 77°F), with excursions permitted between 15°C and 30°C (59°F to 86°F) according to United States Pharmacopeia (USP) guidelines. Protect the container from excessive moisture, heat, and direct sunlight. Keep the bottle tightly closed when not in use. Do not use the medication beyond the expiration date printed on the prescription label or original packaging. Store safely out of reach of children and pets.

Common Questions

Q: What happens if PhosLo is taken without food?

A: Taking PhosLo on an empty stomach significantly reduces its ability to bind dietary phosphate, as there is no food in the gastrointestinal tract to interact with. Instead, a higher proportion of the calcium is absorbed systemically into the bloodstream, increasing the risk of hypercalcemia without achieving the intended therapeutic effect of lowering serum phosphorus.

Q: Is it safe to take over-the-counter calcium supplements alongside PhosLo?

A: Additional calcium supplements should generally be avoided unless specifically prescribed and monitored by a nephrologist. PhosLo already delivers a substantial amount of elemental calcium (169 mg per 667 mg gelcap), and supplemental calcium increases the cumulative daily intake, heightening the risk of elevated serum calcium levels and vascular calcification.

Q: How quickly does PhosLo start lowering serum phosphorus levels?

A: PhosLo begins binding dietary phosphate in the digestive tract immediately upon administration with a meal. However, measurable reductions in systemic serum phosphorus levels generally require several days to weeks of consistent use, alongside dietary phosphate restriction and scheduled dialysis sessions.

Q: Can PhosLo be used during pregnancy or while breastfeeding?

A: Animal reproduction studies have not been conducted with PhosLo. It is unknown whether calcium acetate can cause fetal harm when administered to a pregnant woman or affect reproductive capacity. PhosLo should be given to a pregnant woman only if clearly needed and under strict nephrological supervision. Maternal serum calcium levels must be monitored closely during pregnancy and lactation.

Q: How frequently will blood tests be required while taking PhosLo?

A: Serum calcium and phosphorus levels are typically measured twice weekly during the initiation phase and dose titration of PhosLo. Once stable maintenance levels are achieved, blood tests are performed routinely as part of standard monthly or biweekly lab work for ESRD patients on dialysis.

In accordance with FDA requirements.

This text is for informational purposes only and does not constitute individual medical advice.

Additional information
Dosage

667mg

Package

20 pills

,

30 pills

,

60 pills

,

90 pills

,

120 pills

,

180 pills

,

270 pills

,

360 pills

Ενεργός Ουσία